Senate HELP Panel’s Confounded Markup Points To Challenges Ahead For Chairman Sanders

Session on PBM and generic legislation brought to a halt by Republican objections to amendments targeting FDA disclosure of inactive ingredient concentrations in brands, method-of-use patents, and using REMS to extend patent protection.

Bernie Sanders grinning at HELP markup on 2 May 2023
Sanders seemed happy for the committee session to end. • Source: Screenshot

The Senate Health Education Labor and Pensions Committee suspended its markup on 2 May of four bipartisan bills designed to lower prescription drug prices amidst an unusually public disagreement between Chair Bernie Sanders, D-VT, and Republicans on the panel.

GOP members objected to what they described as primarily procedural issues stemming from Sanders diverging from an prior agreement with...

More from Pricing Debate

More from Market Access